Low Prevalence of Interferon-α Autoantibodies in People Experiencing Long COVID Symptoms, 2022, Michael J Peluso et al

Recent paper on anti-interferon antibodies, which are probably NOT part of the pathophysiology of long COVID even though they are important in the risk of acute COVID.

Abstract
Interferon (IFN)-specific autoantibodies have been implicated in severe COVID-19 and have been proposed as a potential driver of the persistent symptoms characterizing Long COVID, a type of post-acute sequelae of SARS-CoV-2 infection (PASC).

We report than only two of 215 SARS-CoV-2 convalescent participants tested over 394 timepoints, including 121 people experiencing Long COVID symptoms, had detectable IFN-α2 antibodies. Both had been hospitalized during the acute phase of the infection. These data suggest that persistent anti-IFN antibodies, although a potential driver of severe COVID-19, are unlikely to contribute to Long COVID symptoms in the post-acute phase of the infection.

https://academic.oup.com/jid/advanc...is/jiac372/6696027?searchresult=1&login=false

 

This shouldn't be too surprising since we know it isn't severity of the acute symptoms that lead to LongCOVID.